1ken › Citations

An antibody that prevents the hemagglutinin low pH fusogenic transition.

Barbey-Martin C, Gigant B, Bizebard T, Calder LJ, Wharton SA, Skehel JJ, Knossow M
Virology 294 70-4 (2002)
Cited: 134 times
EuropePMC logo PMID: 11886266

Abstract

We have determined the structure of a complex of influenza hemagglutinin (HA) with an antibody that binds simultaneously to the membrane-distal domains of two HA monomers, effectively cross-linking them. The antibody prevents the low pH structural transition of HA that is required for its membrane fusion activity, providing evidence that a rearrangement of HA membrane-distal domains is an essential component of the transition.

Reviews - 1ken mentioned but not cited (6)

  1. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC. Viruses 6 1294-1316 (2014)
  2. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Julien JP, Lee PS, Wilson IA. Immunol. Rev. 250 180-198 (2012)
  3. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Lee PS, Wilson IA. Curr. Top. Microbiol. Immunol. 386 323-341 (2015)
  4. A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. Wu NC, Wilson IA. J. Mol. Biol. 429 2694-2709 (2017)
  5. Antibody specific epitope prediction-emergence of a new paradigm. Sela-Culang I, Ofran Y, Peters B. Curr Opin Virol 11 98-102 (2015)
  6. Analysis of the conserved protective epitopes of hemagglutinin on influenza A viruses. Jiao C, Wang B, Chen P, Jiang Y, Liu J. Front Immunol 14 1086297 (2023)

Articles - 1ken mentioned but not cited (36)

  1. Antibody recognition of a highly conserved influenza virus epitope. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Science 324 246-251 (2009)
  2. A highly conserved neutralizing epitope on group 2 influenza A viruses. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J. Science 333 843-850 (2011)
  3. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC. Proc. Natl. Acad. Sci. U.S.A. 108 14216-14221 (2011)
  4. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. Kringelum JV, Lundegaard C, Lund O, Nielsen M. PLoS Comput. Biol. 8 e1002829 (2012)
  5. Antibody-protein interactions: benchmark datasets and prediction tools evaluation. Ponomarenko JV, Bourne PE. BMC Struct. Biol. 7 64 (2007)
  6. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, Brown SA, Surman S, Wilson ZS, Bradley P, Hurwitz J, Chi H, Doherty PC, Thomas PG, McGargill MA. Nat. Immunol. 14 1266-1276 (2013)
  7. Structural analysis of B-cell epitopes in antibody:protein complexes. Kringelum JV, Nielsen M, Padkjær SB, Lund O. Mol. Immunol. 53 24-34 (2013)
  8. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, Kurosawa Y, Wilson IA. Nat Commun 5 3614 (2014)
  9. Quadrivalent influenza nanoparticle vaccines induce broad protection. Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo M. Nature 592 623-628 (2021)
  10. Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE, Wilson IA, Basler CF. PLoS Pathog. 8 e1003067 (2012)
  11. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, Air GM. PLoS ONE 7 e41895 (2012)
  12. Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model. Guarnaccia T, Carolan LA, Maurer-Stroh S, Lee RT, Job E, Reading PC, Petrie S, McCaw JM, McVernon J, Hurt AC, Kelso A, Mosse J, Barr IG, Laurie KL. PLoS Pathog. 9 e1003354 (2013)
  13. Predicting protein-protein interface residues using local surface structural similarity. Jordan RA, El-Manzalawy Y, Dobbs D, Honavar V. BMC Bioinformatics 13 41 (2012)
  14. Changed epitopes drive the antigenic drift for influenza A (H3N2) viruses. Huang JW, Yang JM. BMC Bioinformatics 12 Suppl 1 S31 (2011)
  15. Protein-protein binding site identification by enumerating the configurations. Guo F, Li SC, Wang L, Zhu D. BMC Bioinformatics 13 158 (2012)
  16. Tertiary structure-based prediction of conformational B-cell epitopes through B factors. Ren J, Liu Q, Ellis J, Li J. Bioinformatics 30 i264-73 (2014)
  17. Selective pressure to increase charge in immunodominant epitopes of the H3 hemagglutinin influenza protein. Pan K, Long J, Sun H, Tobin GJ, Nara PL, Deem MW. J. Mol. Evol. 72 90-103 (2011)
  18. Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Winarski KL, Thornburg NJ, Yu Y, Sapparapu G, Crowe JE, Spiller BW. Proc. Natl. Acad. Sci. U.S.A. 112 9346-9351 (2015)
  19. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Bangaru S, Zhang H, Gilchuk IM, Voss TG, Irving RP, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T, Richt JA, Albrecht RA, Vanderven HA, Bombardi R, Kent SJ, Ward AB, Wilson IA, Crowe JE. Nat Commun 9 2669 (2018)
  20. Structural interface parameters are discriminatory in recognising near-native poses of protein-protein interactions. Malhotra S, Sankar K, Sowdhamini R. PLoS One 9 e80255 (2014)
  21. Analysis of antigenically important residues in human influenza A virus in terms of B-cell epitopes. Lees WD, Moss DS, Shepherd AJ. J. Virol. 85 8548-8555 (2011)
  22. In silico structural homology modelling and docking for assessment of pandemic potential of a novel H7N9 influenza virus and its ability to be neutralized by existing anti-hemagglutinin antibodies. Rajapaksha H, Petrovsky N. PLoS ONE 9 e102618 (2014)
  23. Large-scale analysis of B-cell epitopes on influenza virus hemagglutinin - implications for cross-reactivity of neutralizing antibodies. Sun J, Kudahl UJ, Simon C, Cao Z, Reinherz EL, Brusic V. Front Immunol 5 38 (2014)
  24. A complete, multi-level conformational clustering of antibody complementarity-determining regions. Nikoloudis D, Pitts JE, Saldanha JW. PeerJ 2 e456 (2014)
  25. A likelihood-based index of protein protein binding affinities with application to influenza HA escape from antibodies. Watabe T, Kishino H, de Oliveira Martins L, Kitazoe Y. Mol. Biol. Evol. 24 1627-1638 (2007)
  26. Anti-Hemagglutinin Antibody Derived Lead Peptides for Inhibitors of Influenza Virus Binding. Memczak H, Lauster D, Kar P, Di Lella S, Volkmer R, Knecht V, Herrmann A, Ehrentreich-Förster E, Bier FF, Stöcklein WF. PLoS ONE 11 e0159074 (2016)
  27. HASP server: a database and structural visualization platform for comparative models of influenza A hemagglutinin proteins. Ambroggio XI, Dommer J, Gopalan V, Dunham EJ, Taubenberger JK, Hurt DE. BMC Bioinformatics 14 197 (2013)
  28. A small-molecule fragment that emulates binding of receptor and broadly neutralizing antibodies to influenza A hemagglutinin. Kadam RU, Wilson IA. Proc. Natl. Acad. Sci. U.S.A. 115 4240-4245 (2018)
  29. Computational Identification of Antibody Epitopes on the Dengue Virus NS1 Protein. Jones ML, Legge FS, Lebani K, Mahler SM, Young PR, Watterson D, Treutlein HR, Zeng J. Molecules 22 (2017)
  30. FluKB: A Knowledge-Based System for Influenza Vaccine Target Discovery and Analysis of the Immunological Properties of Influenza Viruses. Simon C, Kudahl UJ, Sun J, Olsen LR, Zhang GL, Reinherz EL, Brusic V. J Immunol Res 2015 380975 (2015)
  31. Predicting Fixation Tendencies of the H3N2 Influenza Virus by Free Energy Calculation. Pan K, Deem MW. J Chem Theory Comput 7 1259-1272 (2011)
  32. RosettaCM for antibodies with very long HCDR3s and low template availability. Kodali P, Schoeder CT, Schmitz S, Crowe JE, Meiler J. Proteins 89 1458-1472 (2021)
  33. Structural Basis for the Broad, Antibody-Mediated Neutralization of H5N1 Influenza Virus. Lin Q, Li T, Chen Y, Lau SY, Wei M, Zhang Y, Zhang Z, Yao Q, Li J, Li Z, Wang D, Zheng Q, Yu H, Gu Y, Zhang J, Chen H, Li S, Xia N. J. Virol. 92 (2018)
  34. The Analysis of B-Cell Epitopes of Influenza Virus Hemagglutinin. Shcherbinin DN, Alekseeva SV, Shmarov MM, Smirnov YA, Naroditskiy BS, Gintsburg AL. Acta Naturae 8 13-20 (2016)
  35. A bioinformatic approach to check the spatial epitope structure of an immunogenic protein coded by DNA vaccine plasmids. Ghaemi Bafghi M, Bassami MR, Hashemi Tabar GR, Saberi MR, Haghparast AR, Dehghani H. J Theor Biol 380 315-320 (2015)
  36. Molecular-level simulation of pandemic influenza glycoproteins. Amaro RE, Li WW. Methods Mol. Biol. 819 575-594 (2012)


Reviews citing this publication (20)

  1. The many mechanisms of viral membrane fusion proteins. Earp LJ, Delos SE, Park HE, White JM. Curr. Top. Microbiol. Immunol. 285 25-66 (2005)
  2. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. Nat. Rev. Microbiol. 6 143-155 (2008)
  3. Variation and infectivity neutralization in influenza. Knossow M, Skehel JJ. Immunology 119 1-7 (2006)
  4. How innate immune mechanisms contribute to antibody-enhanced viral infections. Ubol S, Halstead SB. Clin. Vaccine Immunol. 17 1829-1835 (2010)
  5. Influenza virus-mediated membrane fusion: determinants of hemagglutinin fusogenic activity and experimental approaches for assessing virus fusion. Hamilton BS, Whittaker GR, Daniel S. Viruses 4 1144-1168 (2012)
  6. Protein-protein docking dealing with the unknown. Moreira IS, Fernandes PA, Ramos MJ. J Comput Chem 31 317-342 (2010)
  7. Structural basis of influenza virus neutralization. Han T, Marasco WA. Ann. N. Y. Acad. Sci. 1217 178-190 (2011)
  8. Influenza Hemagglutinin Structures and Antibody Recognition. Wu NC, Wilson IA. Cold Spring Harb Perspect Med 10 a038778 (2020)
  9. Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Acosta PL, Caballero MT, Polack FP. Clin. Vaccine Immunol. 23 189-195 (2015)
  10. An overview of influenza haemagglutinin and neuraminidase. Skehel J. Biologicals 37 177-178 (2009)
  11. Genome-wide studies of protein-protein interaction. Janin J, Séraphin B. Curr. Opin. Struct. Biol. 13 383-388 (2003)
  12. Signaling by Antibodies: Recent Progress. Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Annu. Rev. Immunol. 35 285-311 (2017)
  13. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Kim H, Webster RG, Webby RJ. Viral Immunol. 31 174-183 (2018)
  14. Mechanisms of influenza viral membrane fusion. Blijleven JS, Boonstra S, Onck PR, van der Giessen E, van Oijen AM. Semin. Cell Dev. Biol. 60 78-88 (2016)
  15. Next-generation influenza vaccines: opportunities and challenges. Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Nat Rev Drug Discov 19 239-252 (2020)
  16. Passive immune neutralization strategies for prevention and control of influenza A infections. Ye J, Shao H, Perez DR. Immunotherapy 4 175-186 (2012)
  17. Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion. Garcia NK, Lee KK. Viruses 8 (2016)
  18. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Front Immunol 12 786617 (2021)
  19. Structural Insights for Anti-Influenza Vaccine Design. Han L, Chen C, Han X, Lin S, Ao X, Han X, Wang J, Ye H. Comput Struct Biotechnol J 17 475-483 (2019)
  20. The Power and Limitations of Influenza Virus Hemagglutinin Assays. Ustinov NB, Zavyalova EG, Smirnova IG, Kopylov AM. Biochemistry Mosc. 82 1234-1248 (2017)

Articles citing this publication (72)

  1. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. Nat. Struct. Mol. Biol. 16 265-273 (2009)
  2. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. Science 333 850-856 (2011)
  3. CAPRI: a Critical Assessment of PRedicted Interactions. Janin J, Henrick K, Moult J, Eyck LT, Sternberg MJ, Vajda S, Vakser I, Wodak SJ, Critical Assessment of PRedicted Interactions. Proteins 52 2-9 (2003)
  4. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Nat. Med. 20 143-151 (2014)
  5. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. Nat. Med. 15 34-41 (2009)
  6. Assessment of blind predictions of protein-protein interactions: current status of docking methods. Méndez R, Leplae R, De Maria L, Wodak SJ. Proteins 52 51-67 (2003)
  7. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O'Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA. Nature 489 526-532 (2012)
  8. ICM-DISCO docking by global energy optimization with fully flexible side-chains. Fernández-Recio J, Totrov M, Abagyan R. Proteins 52 113-117 (2003)
  9. Assessing predictions of protein-protein interaction: the CAPRI experiment. Janin J. Protein Sci. 14 278-283 (2005)
  10. Evaluation of protein docking predictions using Hex 3.1 in CAPRI rounds 1 and 2. Ritchie DW. Proteins 52 98-106 (2003)
  11. Mechanism of neutralization of influenza virus infectivity by antibodies. Knossow M, Gaudier M, Douglas A, Barrère B, Bizebard T, Barbey C, Gigant B, Skehel JJ. Virology 302 294-298 (2002)
  12. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y, Takada A, Wilson IA. Proc. Natl. Acad. Sci. U.S.A. 109 17040-17045 (2012)
  13. Crystal structure of unliganded influenza B virus hemagglutinin. Wang Q, Cheng F, Lu M, Tian X, Ma J. J. Virol. 82 3011-3020 (2008)
  14. Structural changes in Influenza virus at low pH characterized by cryo-electron tomography. Fontana J, Cardone G, Heymann JB, Winkler DC, Steven AC. J. Virol. 86 2919-2929 (2012)
  15. Structural characterization of an early fusion intermediate of influenza virus hemagglutinin. Xu R, Wilson IA. J. Virol. 85 5172-5182 (2011)
  16. Mechanisms of hemagglutinin targeted influenza virus neutralization. Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, van Oijen AM, Vogels R, Friesen RH. PLoS ONE 8 e80034 (2013)
  17. Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS. PLoS Pathog. 11 e1005035 (2015)
  18. ZDOCK predictions for the CAPRI challenge. Chen R, Tong W, Mintseris J, Li L, Weng Z. Proteins 52 68-73 (2003)
  19. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Saphire EO. Cell 160 904-912 (2015)
  20. Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Bai Y, Ye L, Tesar DB, Song H, Zhao D, Björkman PJ, Roopenian DC, Zhu X. Proc. Natl. Acad. Sci. U.S.A. 108 18406-18411 (2011)
  21. Successful discrimination of protein interactions. Camacho CJ, Gatchell DW. Proteins 52 92-97 (2003)
  22. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. Schneemann A, Speir JA, Tan GS, Khayat R, Ekiert DC, Matsuoka Y, Wilson IA. J. Virol. 86 11686-11697 (2012)
  23. Comment Universal epitopes of influenza virus hemagglutinins? Wang TT, Palese P. Nat. Struct. Mol. Biol. 16 233-234 (2009)
  24. A comprehensive map of the influenza A virus replication cycle. Matsuoka Y, Matsumae H, Katoh M, Eisfeld AJ, Neumann G, Hase T, Ghosh S, Shoemaker JE, Lopes TJ, Watanabe T, Watanabe S, Fukuyama S, Kitano H, Kawaoka Y. BMC Syst Biol 7 97 (2013)
  25. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. Iba Y, Fujii Y, Ohshima N, Sumida T, Kubota-Koketsu R, Ikeda M, Wakiyama M, Shirouzu M, Okada J, Okuno Y, Kurosawa Y, Yokoyama S. J. Virol. 88 7130-7144 (2014)
  26. Three-dimensional window analysis for detecting positive selection at structural regions of proteins. Suzuki Y. Mol. Biol. Evol. 21 2352-2359 (2004)
  27. A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin. Zhu X, Guo YH, Jiang T, Wang YD, Chan KH, Li XF, Yu W, McBride R, Paulson JC, Yuen KY, Qin CF, Che XY, Wilson IA. J. Virol. 87 12619-12635 (2013)
  28. Diversifying selective pressure on influenza B virus hemagglutinin. Shen J, Kirk BD, Ma J, Wang Q. J. Med. Virol. 81 114-124 (2009)
  29. Influenza A virus hemagglutinin trimerization completes monomer folding and antigenicity. Magadán JG, Khurana S, Das SR, Frank GM, Stevens J, Golding H, Bennink JR, Yewdell JW. J. Virol. 87 9742-9753 (2013)
  30. Potential neutralizing antibodies discovered for novel corona virus using machine learning. Magar R, Yadav P, Barati Farimani A. Sci Rep 11 5261 (2021)
  31. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Wan H, Yang H, Shore DA, Garten RJ, Couzens L, Gao J, Jiang L, Carney PJ, Villanueva J, Stevens J, Eichelberger MC. Nat Commun 6 6114 (2015)
  32. In silico characterization of the functional and structural modules of the hemagglutinin protein from the swine-origin influenza virus A (H1N1)-2009. Sun Y, Shi Y, Zhang W, Li Q, Liu D, Vavricka C, Yan J, Gao GF. Sci China Life Sci 53 633-642 (2010)
  33. Evolutionary dynamics of N-glycosylation sites of influenza virus hemagglutinin. Cherry JL, Lipman DJ, Nikolskaya A, Wolf YI. PLoS Curr 1 RRN1001 (2009)
  34. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. de Vries RD, Nieuwkoop NJ, Pronk M, de Bruin E, Leroux-Roels G, Huijskens EGW, van Binnendijk RS, Krammer F, Koopmans MPG, Rimmelzwaan GF. Vaccine 35 238-247 (2017)
  35. Evaluation of the 3D-Dock protein docking suite in rounds 1 and 2 of the CAPRI blind trial. Smith GR, Sternberg MJ, CAPRI blind trial. Proteins 52 74-79 (2003)
  36. pH-induced conformational change of the rotavirus VP4 spike: implications for cell entry and antibody neutralization. Pesavento JB, Crawford SE, Roberts E, Estes MK, Prasad BV. J. Virol. 79 8572-8580 (2005)
  37. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Chai N, Swem LR, Park S, Nakamura G, Chiang N, Estevez A, Fong R, Kamen L, Kho E, Reichelt M, Lin Z, Chiu H, Skippington E, Modrusan Z, Stinson J, Xu M, Lupardus P, Ciferri C, Tan MW. Nat Commun 8 14234 (2017)
  38. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. Thornburg NJ, Nannemann DP, Blum DL, Belser JA, Tumpey TM, Deshpande S, Fritz GA, Sapparapu G, Krause JC, Lee JH, Ward AB, Lee DE, Li S, Winarski KL, Spiller BW, Meiler J, Crowe JE. J. Clin. Invest. 123 4405-4409 (2013)
  39. Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection. Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, Palamara AT, Polonelli L. Antimicrob. Agents Chemother. 52 4331-4337 (2008)
  40. Combining interface core and whole interface descriptors in postscan processing of protein-protein docking models. Kowalsman N, Eisenstein M. Proteins 77 297-318 (2009)
  41. Prediction of the unknown: inspiring experience with the CAPRI experiment. Ben-Zeev E, Berchanski A, Heifetz A, Shapira B, Eisenstein M. Proteins 52 41-46 (2003)
  42. Computational analysis of antigenic epitopes of avian influenza A (H7N9) viruses. Liu M, Song T, Hua S, Wu A, Jiang T. Sci China Life Sci 58 687-693 (2015)
  43. Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity. Wang W, DeFeo CJ, Alvarado-Facundo E, Vassell R, Weiss CD. J. Virol. 89 10602-10611 (2015)
  44. Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization. Koromyslova AD, Hansman GS. PLoS Pathog. 13 e1006636 (2017)
  45. Functions of Antibodies. Forthal DN. Microbiol Spectr 2 1-17 (2014)
  46. Progress in computation and amide hydrogen exchange for prediction of protein-protein complexes. Law D, Hotchko M, Ten Eyck L. Proteins 60 302-307 (2005)
  47. Mapping antibody epitopes of the avian H5N1 influenza virus. Yen HL, Peiris JS. PLoS Med. 6 e1000064 (2009)
  48. Preparation of monoclonal antibodies against poor immunogenic avian influenza virus proteins. He JL, Hsieh MS, Chiu YC, Juang RH, Wang CH. J. Immunol. Methods 387 43-50 (2013)
  49. Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus. Wilson JR, Guo Z, Tzeng WP, Garten RJ, Xiyan X, Blanchard EG, Blanchfield K, Stevens J, Katz JM, York IA. Virology 485 252-262 (2015)
  50. N-linked glycans on influenza A H3N2 hemagglutinin constrain binding of host antibodies, but shielding is limited. Pentiah K, Lees WD, Moss DS, Shepherd AJ. Glycobiology 25 124-132 (2015)
  51. Structural transitions in influenza haemagglutinin at membrane fusion pH. Benton DJ, Gamblin SJ, Rosenthal PB, Skehel JJ. Nature 583 150-153 (2020)
  52. Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans. Roozendaal R, Tolboom J, Roos A, Riahi S, Theeuwsen J, Bujny MV, Klaren V, Korse HJ, Dekking L, Grootenhuis A, Weverling GJ, Koudstaal W, Goudsmit J, Radošević K. PLoS ONE 9 e103550 (2014)
  53. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies. Roos A, Roozendaal R, Theeuwsen J, Riahi S, Vaneman J, Tolboom J, Dekking L, Koudstaal W, Goudsmit J, Radošević K. Vaccine 33 1739-1747 (2015)
  54. In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA, and UDA as Inhibitors of Influenza A and B Virus Replication. Vanderlinden E, Van Winkel N, Naesens L, Van Damme EJM, Persoons L, Schols D. Antimicrob Agents Chemother 65 e01732-20 (2021)
  55. An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein. Yoon A, Yi KS, Chang SY, Kim SH, Song M, Choi JA, Bourgeois M, Hossain MJ, Chen LM, Donis RO, Kim H, Lee Y, Hwang DB, Min JY, Chang SJ, Chung J. PLoS ONE 10 e0141312 (2015)
  56. Dissection of Epitope-Specific Mechanisms of Neutralization of Influenza Virus by Intact IgG and Fab Fragments. Williams JA, Gui L, Hom N, Mileant A, Lee KK. J. Virol. 92 (2018)
  57. Exploration of binding and inhibition mechanism of a small molecule inhibitor of influenza virus H1N1 hemagglutinin by molecular dynamics simulation. Guan S, Wang T, Kuai Z, Qian M, Tian X, Zhang X, Yu Y, Wang S, Zhang H, Li H, Kong W, Shan Y. Sci Rep 7 3786 (2017)
  58. Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD). Mendoza M, Ballesteros A, Qiu Q, Pow Sang L, Shashikumar S, Casares S, Brumeanu TD. Hum Vaccin Immunother 14 345-360 (2018)
  59. Influenza A HA's conserved epitopes and broadly neutralizing antibodies: a prediction method. Ren J, Ellis J, Li J. J Bioinform Comput Biol 12 1450023 (2014)
  60. Serologic screenings for H7N9 from three sources among high-risk groups in the early stage of H7N9 circulation in Guangdong Province, China. Wu J, Zou L, Ni H, Pei L, Zeng X, Liang L, Zhong H, He J, Song Y, Kang M, Zhang X, Lin J, Ke C. Virol. J. 11 184 (2014)
  61. Activation and Induction of Antigen-Specific T Follicular Helper Cells Play a Critical Role in Live-Attenuated Influenza Vaccine-Induced Human Mucosal Anti-influenza Antibody Response. Aljurayyan A, Puksuriwong S, Ahmed M, Sharma R, Krishnan M, Sood S, Davies K, Rajashekar D, Leong S, McNamara PS, Gordon S, Zhang Q. J. Virol. 92 (2018)
  62. A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax. Arévalo MT, Li J, Diaz-Arévalo D, Chen Y, Navarro A, Wu L, Yan Y, Zeng M. Immunology 150 276-289 (2017)
  63. An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody. Sano K, Saito S, Suzuki T, Kotani O, Ainai A, van Riet E, Tabata K, Saito K, Takahashi Y, Yokoyama M, Sato H, Maruno T, Usami K, Uchiyama S, Ogawa-Goto K, Hasegawa H. PLoS One 16 e0245244 (2021)
  64. Antibody blockade of CD96 by distinct molecular mechanisms. Lee PS, Chau B, Barman I, Bee C, Jashnani A, Hogan JM, Aguilar B, Dollinger G, Rajpal A, Strop P. MAbs 13 1979800 (2021)
  65. Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy. Zorzan M, Castellan M, Gasparotto M, Dias de Melo G, Zecchin B, Leopardi S, Chen A, Rosato A, Angelini A, Bourhy H, Corti D, Cendron L, De Benedictis P. Front Immunol 14 1186063 (2023)
  66. Development of a high-throughput assay to detect antibody inhibition of low pH induced conformational changes of influenza virus hemagglutinin. Trost JF, LeMasters EH, Liu F, Carney P, Lu X, Sugawara K, Hongo S, Stevens J, Steinhauer DA, Tumpey T, Katz JM, Levine MZ, Li ZN. PLoS ONE 13 e0199683 (2018)
  67. Human Influenza Virus Hemagglutinins Contain Conserved Oligomannose N-Linked Glycans Allowing Potent Neutralization by Lectins. Thompson AJ, Cao L, Ma Y, Wang X, Diedrich JK, Kikuchi C, Willis S, Worth C, McBride R, Yates JR, Paulson JC. Cell Host Microbe 27 725-735.e5 (2020)
  68. Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses. Li T, Chen J, Zheng Q, Xue W, Zhang L, Rong R, Zhang S, Wang Q, Hong M, Zhang Y, Cui L, He M, Lu Z, Zhang Z, Chi X, Li J, Huang Y, Wang H, Tang J, Ying D, Zhou L, Wang Y, Yu H, Zhang J, Gu Y, Chen Y, Li S, Xia N. Nat Commun 13 5182 (2022)
  69. Influenza antigenic drift: what is the driving force? Wang Q. Cellscience 6 1-8 (2010)
  70. Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses. Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y. Front Microbiol 9 2660 (2018)
  71. Live attenuated influenza vaccine induces broadly cross-reactive mucosal antibody responses to different influenza strains in tonsils. Mahallawi WH, Zhang Q. Saudi J Biol Sci 30 103809 (2023)
  72. Structural intermediates in the low pH-induced transition of influenza hemagglutinin. Gao J, Gui M, Xiang Y. PLoS Pathog 16 e1009062 (2020)


Related citations provided by authors (1)

  1. A neutralizing antibody Fab-influenza haemagglutinin complex with an unprecedented 2:1 stoichiometry: characterization and crystallization.. Gigant B, Barbey-Martin C, Bizebard T, Fleury D, Daniels R, Skehel JJ, Knossow M Acta Crystallogr D Biol Crystallogr 56 1067-9 (2000)

Quick links